Trial Profile
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; MRNA 2752 (Primary)
- Indications Advanced breast cancer; Carcinoma; Diffuse large B cell lymphoma; Head and neck cancer; Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Moderna Therapeutics
- 19 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2022 Planned End Date changed from 30 Jan 2023 to 1 Apr 2025.
- 20 Dec 2022 Planned primary completion date changed from 30 Jan 2023 to 15 May 2024.